| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Endocrine Research Unit (C.A.C., L.K.B.), Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905; and Department of Pediatrics (S.K.D., D.R.P.), Baylor College of Medicine, Texas Childrens Hospital, Houston, Texas 77030
Address all correspondence and requests for reprints to: Cheryl A. Conover, Ph.D., Mayo Clinic, 200 First Street SW, 5194 Joseph, Rochester, Minnesota 55905. E-mail: conover.cheryl{at}mayo.edu
Cell-association and processing of insulin-like growth factor binding protein-3 (IGFBP-3) by cultured bovine fibroblasts results in markedly enhanced type I IGF receptor signaling at a step distal to ligand binding. The purpose of the present study was to determine the intracellular mediators of IGFBP-3s potentiating effect. Preincubation of cultured bovine fibroblasts with 50 nM IGFBP-3 had no effect alone, but enhanced by 3- to 4-fold IGF-I-stimulated 3H-aminoisobutryric acid (AIB) uptake. IGFBP-3-induced potentiation was specifically prevented if an inhibitor of phosphatidylinositol 3 (PI3)-kinase activation (LY294002), but not an inhibitor of mitogen-activated protein kinase activation (PD98059), was present during the preincubation period. IGFBP-3 did not directly activate the downstream effector of PI3-kinase, protein kinase B (PKB)/Akt. However, the sensitivity of PKB/Akt to activation by IGF-I was increased by 2- to 4-fold with IGFBP-3 pretreatment. This increased sensitivity was accompanied by altered mobility of PKB/Akt on SDS-polyacrylamide gels, suggestive of a diminished phosphorylation state. Consistent with this, okadaic acid, a potent serine/threonine phosphatase inhibitor, was able to block the potentiation effect of IGFBP-3 and prevent the altered mobility of the PKB/Akt molecule in response to IGFBP-3 treatment. PKB/Akt immunoprecipitated from IGFBP-3-pretreated cells was no longer recognized by an antibody specific for phosphorylated threonine followed by proline. These data indicate that IGFBP-3 modulates type I IGF receptor signaling through an effect on PI-3-kinase pathway substrates and suggest a novel mechanism of dephosphorylation whereby PKB/Akt is transformed into a more sensitive substrate of type I IGF receptor signaling.
This article has been cited by other articles:
![]() |
Z. T. Resch, C. Oxvig, L. K. Bale, and C. A. Conover Stress-Activated Signaling Pathways Mediate the Stimulation of Pregnancy-Associated Plasma Protein-A Expression in Cultured Human Fibroblasts Endocrinology, February 1, 2006; 147(2): 885 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kiepe, S. Ciarmatori, A. Haarmann, and B. Tonshoff Differential expression of IGF system components in proliferating vs. differentiating growth plate chondrocytes: the functional role of IGFBP-5 Am J Physiol Endocrinol Metab, February 1, 2006; 290(2): E363 - E371. [Abstract] [Full Text] [PDF] |
||||
![]() |
J M Fleming, B J Leibowitz, D E Kerr, and W S Cohick IGF-I differentially regulates IGF-binding protein expression in primary mammary fibroblasts and epithelial cells J. Endocrinol., July 1, 2005; 186(1): 165 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Ongeri, M. F. Verderame, and J. M. Hammond Follicle-Stimulating Hormone Induction of Ovarian Insulin-Like Growth Factor-Binding Protein-3 Transcription Requires a TATA Box-Binding Protein and the Protein Kinase A and Phosphatidylinositol-3 Kinase Pathways Mol. Endocrinol., July 1, 2005; 19(7): 1837 - 1848. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Silha, Y. Gui, S. Mishra, A. Leckstrom, P. Cohen, and L. J. Murphy Overexpression of Gly56/Gly80/Gly81-Mutant Insulin-Like Growth Factor-Binding Protein-3 in Transgenic Mice Endocrinology, March 1, 2005; 146(3): 1523 - 1531. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C.J.P. Gielen, E. E. Hanekamp, L. J. Blok, F. J. Huikeshoven, and C. W. Burger Steroid-Modulated Proliferation of Human Endometrial Carcinoma Cell Lines: Any Role for Insulin-like Growth Factor Signaling? Reproductive Sciences, January 1, 2005; 12(1): 58 - 64. [Abstract] [PDF] |
||||
![]() |
A. J. Butt, J. L. Martin, K. A. Dickson, F. McDougall, S. M. Firth, and R. C. Baxter Insulin-Like Growth Factor Binding Protein-3 Expression Is Associated with Growth Stimulation of T47D Human Breast Cancer Cells: The Role of Altered Epidermal Growth Factor Signaling J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1950 - 1956. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Palermo, P. Manduca, E. Gazzerro, L. Foppiani, D. Segat, and A. Barreca Potentiating role of IGFBP-2 on IGF-II-stimulated alkaline phosphatase activity in differentiating osteoblasts Am J Physiol Endocrinol Metab, April 1, 2004; 286(4): E648 - E657. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Edmondson, S. P. Thumiger, G. A. Werther, and C. J. Wraight Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems Endocr. Rev., December 1, 2003; 24(6): 737 - 764. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Longobardi, M. Torello, C. Buckway, L. O'Rear, W. A. Horton, V. Hwa, C. T. Roberts Jr., F. Chiarelli, R. G. Rosenfeld, and A. Spagnoli A Novel Insulin-Like Growth Factor (IGF)-Independent Role for IGF Binding Protein-3 in Mesenchymal Chondroprogenitor Cell Apoptosis Endocrinology, May 1, 2003; 144(5): 1695 - 1702. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Martin, S. M. Weenink, and R. C. Baxter Insulin-like Growth Factor-binding Protein-3 Potentiates Epidermal Growth Factor Action in MCF-10A Mammary Epithelial Cells. INVOLVEMENT OF p44/42 AND p38 MITOGEN-ACTIVATED PROTEIN KINASES J. Biol. Chem., January 24, 2003; 278(5): 2969 - 2976. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Firth and R. C. Baxter Cellular Actions of the Insulin-Like Growth Factor Binding Proteins Endocr. Rev., December 1, 2002; 23(6): 824 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kandasamy and R. K. Srivastava Role of the Phosphatidylinositol 3'-Kinase/PTEN/Akt Kinase Pathway in Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Non-Small Cell Lung Cancer Cells Cancer Res., September 1, 2002; 62(17): 4929 - 4937. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Spagnoli, M. Torello, S. R. Nagalla, W. A. Horton, P. Pattee, V. Hwa, F. Chiarelli, C. T. Roberts Jr., and R. G. Rosenfeld Identification of STAT-1 as a Molecular Target of IGFBP-3 in the Process of Chondrogenesis J. Biol. Chem., May 17, 2002; 277(21): 18860 - 18867. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Silha, Y. Gui, T. Modric, A. Suwanichkul, S. K. Durham, D. R. Powell, and L. J. Murphy Overexpression of the Acid-Labile Subunit of the IGF Ternary Complex in Transgenic Mice Endocrinology, October 1, 2001; 142(10): 4305 - 4313. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Walker, E. M. Wilson, D. Powell, and Y. Oh Butyrate, a Histone Deacetylase Inhibitor, Activates the Human IGF Binding Protein-3 Promoter in Breast Cancer Cells: Molecular Mechanism Involves an Sp1/Sp3 Multiprotein Complex Endocrinology, September 1, 2001; 142(9): 3817 - 3827. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Modric, J. V. Silha, Z. Shi, Y. Gui, A. Suwanichkul, S. K. Durham, D. R. Powell, and L. J. Murphy Phenotypic Manifestations of Insulin-Like Growth Factor-Binding Protein-3 Overexpression in Transgenic Mice Endocrinology, May 1, 2001; 142(5): 1958 - 1967. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |